Halozyme Therapeutics (HALO) EBITDA (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EBITDA data on file, last reported at $184.5 million in Q1 2026.

• On a quarterly basis, EBITDA rose 30.37% year-over-year to $184.5 million in Q1 2026; TTM through Mar 2026 was $512.0 million, a 14.31% decrease from a year earlier, with the FY2025 full-year figure at $469.0 million, down 14.95% from the prior year.
• EBITDA for Q1 2026 stood at $184.5 million, up from -$92.9 million in the prior quarter.
• Over the last five years, EBITDA for HALO reached as high as $217.9 million in Q3 2025 and fell as low as -$92.9 million in Q4 2025.
• Historically, EBITDA has averaged $106.5 million across 5 years, with a median of $95.5 million in 2024.
• Across the five-year window, EBITDA soared 177.33% in 2023 and sank 152.93% in 2025, its largest moves.
• Year by year, EBITDA stood at $74.5 million in 2022, then jumped by 35.6% to $101.0 million in 2023, then jumped by 73.7% to $175.5 million in 2024, then sank by 152.93% to -$92.9 million in 2025, then jumped by 298.64% to $184.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $184.5 million in Q1 2026, -$92.9 million in Q4 2025, and $217.9 million in Q3 2025.